EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting

Maria Pokorska-Śpiewak, Anna Dobrzeniecka, Ewa Talarek, Małgorzata Aniszewska, Magdalena Marczyńska

European Journal of Clinical Microbiology & Infectious Diseases · 2025

DOI: 10.1007/s10096-025-05320-4 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, 2025. Verfasst von Maria Pokorska-Śpiewak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. maria.pokorska-spiewak@wum.edu.pl. Hauptthemen laut MEDLINE: Sofosbuvir, Antiviral Agents, Hepatitis C, Chronic. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The aim of this study was to analyze the safety and efficacy of sofosbuvir-based regimens (SOF/velpatasvir and SOF/ledipasvir, SOF/VEL and SOF/LDV) for the treatment of hepatitis C in children aged 5-17 years in a real-life setting. METHODS: All participants who received SOF-based regimens beginning in August 2019 were included. The treatment duration was 12 weeks for both the SOF/LDV and SOF/VEL regimens; however, in the case of children infected with HCV genotype 1 and presenting with cirrhosis, the duration of the SOF/LDV treatment was extended to 24 weeks. In all cases, fixed doses of SOF/LDV and SOF/VEL were used adjusted to the patients' age and weight. The primary endpoint for these studies included evaluation of treatment efficacy (defined as sustained virologic response, SVR12, with undetectable HCV RNA at 12 weeks posttreatment). RESULTS: We identified 90 patients aged 5 to 17 years eligible for the study: 50 who were treated with SOF/VEL and 40 who received SOF/LDV. The SVR12 assessment was available for 89 patients. In all of them, SVR12 was achieved (100% efficacy in per-protocol analysis; 99% efficacy in intention-to-treat assessment). One-third of the study participants reported adverse events (AEs) related to antiviral treatment, all of which were mild or moderate. Headache, fatigue, and abdominal pain were the most common symptoms. Some differences in the frequency of AEs according to the DAA used were noted (abdominal pain and asthenia were less common in children treated with SOF/LDV than in those treated with SOF/VEL). No case of treatment discontinuation occurred. CONCLUSION: This study confirms the excellent efficacy and good tolerability of SOF-based regimens for the treatment of hepatitis C in children aged 5 to 17 years in real-life settings, supporting the inclusion of pediatric patients in national treatment policies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SofosbuvirAntiviral AgentsHepatitis C, ChronicHumansChildAdolescentMaleFemaleChild, PreschoolTreatment OutcomeHepacivirusSustained Virologic ResponseCarbamatesHeterocyclic Compounds, 4 or More RingsFluorenesBenzimidazolesDrug Therapy, Combination

Stichwörter der Autor:innen

ChildrenDirect acting antiviralsHepatitis CSofosbuvir/ledipasvirSofosbuvir/velpatasvir

Substanzen

SofosbuvirAntiviral AgentsCarbamatesHeterocyclic Compounds, 4 or More RingsFluorenesBenzimidazoles

Autor:innen und Institutionen

  • Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland. maria.pokorska-spiewak@wum.edu.pl.
  • Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, ul. Wolska 37, Warsaw, 01-201, Poland. maria.pokorska-spiewak@wum.edu.pl.
  • Department of Children's Infectious Diseases, Medical University of Warsaw, Warsaw, Poland.
  • Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, ul. Wolska 37, Warsaw, 01-201, Poland.

Zitieren

APA

Pokorska-Śpiewak, M., Dobrzeniecka, A., Talarek, E., Aniszewska, M., & Marczyńska, M. (2025). Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. European Journal of Clinical Microbiology & Infectious Diseases. https://doi.org/10.1007/s10096-025-05320-4

Vancouver

Pokorska-Śpiewak M, Dobrzeniecka A, Talarek E, Aniszewska M, Marczyńska M. Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting. European Journal of Clinical Microbiology & Infectious Diseases. 2025. doi:10.1007/s10096-025-05320-4

BibTeX
@article{Pokorskapiewak2025,
  author = {Pokorska-Śpiewak, Maria and Dobrzeniecka, Anna and Talarek, Ewa and Aniszewska, Małgorzata and Marczyńska, Magdalena},
  title = {Efficacy and safety of sofosbuvir-based therapies for treating HCV in children: observations from a real-world setting},
  journal = {European Journal of Clinical Microbiology & Infectious Diseases},
  year = {2025},
  doi = {10.1007/s10096-025-05320-4}
}
Kostenlos starten →